Dosing | KISQALI® (ribociclib) Professional Site

For Healthcare Professionals Outside the US
KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)—negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

KISQALI in combination with an AI, regardless of menopausal status¹

kisqali ai

Please refer to the full Summary of Product Characteristics for the recommended dose of the chosen AI

KISQALI in combination with fulvestrant for postmenopausal patients¹

Once-daily dosing with fulvestrant for postmenopausal women

When given with KISQALI, the recommended dose of fulvestrant is 500 mg, administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the full Summary of Product Characteristics for fulvestrant¹
In premenopausal patients, an LHRH agonist should be administered according to current clinical practice guidelines when given with KISQALI¹
KISQALI, an AI, and an LHRH agonist can all be started as early as Day 1 with no need to wait 4 weeks after initiating the LHRH agonist^1,2

dosing image

AI, aromatase inhibitor; CDK, cyclin-dependent kinase.

References: 1. KISQALI [Summary of Product Characteristics]. Novartis Pharma AG; 2019. 2. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2019;19(7):904-915. 3. Ibrance [Summary of Product Characteristics]. Pfizer Inc: 2018. 4. Verzenios [Summary of Product Characteristics]. Eli Lilly and Company; 2018.